Hot off the Press !! 📣📰💪 Porsolt is proud to announce our most recent publication in #Cancers journal, focusing on potential treatments for Glioblastoma. The paper entitled ”Evaluation of Temozolomide…
This one appears in the most recent issue of “International Journal of Molecular Sciences” (Q1 Medicine). The paper highlights the qualities of two clinically approved-drugs for autoimmune disease, Fingolimod and…
Porsolt is thrilled to already have our third paper published for this year: “Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T…
SAFETY REGULATORY PACKAGE Porsolt’s broad expertise and years of preclinical pharmacology experience makes us the ideal partner to conduct your GLP Safety Pharmacology experiments. Porsolt offers safety studies in both…
PAIN Porsolt offers models of acute and chronic pain and inflammation matching the needs of the industry and maintaining a recognized expertise, which addresses pain therapeutic endpoints and pain associated…